← Back to Clinical Trials
Recruiting NCT06466057

NCT06466057 Metacognitive Therapy for Obsessive-Compulsive Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06466057
Status Recruiting
Phase
Sponsor Northeast Normal University
Condition Obsessive-Compulsive Disorder
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2024-06-11
Primary Completion 2024-09-01

Trial Parameters

Condition Obsessive-Compulsive Disorder
Sponsor Northeast Normal University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 80
Sex ALL
Min Age 12 Years
Max Age 60 Years
Start Date 2024-06-11
Completion 2024-09-01
Interventions
Metacognitive TherapyGeneral mental health promotion

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this clinical trial is to learn if metacognitive therapy can be effective in a Chinese sample of obsessive compulsive disorder (OCD) . The main questions it aims to answer are: Can metacognitive therapy significantly reduce participants' levels of obsessive-compulsive symptoms? Can metacognitive therapy significantly improve participants' metacognitive adaptations? The researchers will compare metacognitive therapy to a control condition without psychotherapy to see if metacognitive therapy is effective in treating OCD. Participants will: Receive the metacognitive therapy intervention or under control conditions for 8 to 15 weeks. Be assessed for symptoms and metacognitive beliefs at pre-intervention, post-intervention and 12 weeks post-intervention

Eligibility Criteria

Inclusion Criteria: * two psychiatrists with the title of Deputy Chief Physician or above jointly determine that the above diagnostic criteria were met * education level of junior high school or above, without mental retardation or audio-visual disorders * participation in the study is voluntary, and the informed consent is signed by the patient or his/her guardian Exclusion Criteria: * loss of or insufficient self-awareness, the presence of hallucinations, delusions, and other psychotic symptoms * the presence of severe depression, or self-inflicted suicidal attempts and behaviors * the presence of a history of alcohol or drug abuse * refusal of psychotherapy, or the ineffectiveness of those who had been involved in a full course of psychotherapy.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology